<DOC>
	<DOCNO>NCT02604420</DOCNO>
	<brief_summary>Mortality major thrombotic microangiopathies ( TMAs ) , TTP aHUS , exceed 90 % unless rapidly diagnose appropriately treat . TMAs complicate 10-20 % allogeneic bone marrow hematopoietic stem cell transplant ( alloHSCT ) , convey inferior survival . Multiple etiology propose transplant-associated TMAs ( TA-TMAs ) , infection , graft vs. host disease ( GvHD ) , drug effect rule , treat TTP-like disorder use plasma exchange ( PEx ) . But PEx impact mortality setting . Clear definition pathophysiology TA-TMAs require guide effective treatment . Investigators hypothesize aHUS-type TMA , related dysregulation alternative complement pathway , involve characterize elevate plasma level C5b-9 detectable C5b-9 deposition bone marrow sinusoidal vessel . Investigators hypothesize treatment inhibitor terminal complement component reverse TMA vivo , block endothelial cell damage vitro model system . The data investigator generate observational study TA-TMAs enable prediction development prior overt clinical manifestation , guide appropriate therapy .</brief_summary>
	<brief_title>Identification Treatment Thrombotic Microangiopathies Allogeneic Stem Cell Transplants</brief_title>
	<detailed_description>Investigators plan enroll 120 adult patient undergo allogeneic hematopoietic stem cell transplant follow serially one year . Investigators harvest store -80oC plasma PBMCs , collect bone marrow core biopsy specimens individual baseline , day 28 , 100 , 190 , 365 post-transplant , time relapse primary disease relapse TMA development . These time point , bone marrow procedure , blood draw part ordinary customary followup allogeneic HSCT patient institution . With patient sample investigator : 1 . Determine incidence TMAs fitting criterion Coombs negative hemolytic anemia , thrombocytopenia ( 25 % decrease baseline ) elevate ( 2x baseline ) LDH , schistocytes organ system involvement ( typically increase creatinine new microscopic hematuria proteinuria ) 2 . Determine incidence aHUS-like TMA , i.e. , TMA characterize ADAMTS13 activity plasma &gt; 5 % clinical laboratory finding persist stop calcineurin mTOR inhibitor one half life ( 3-7 day , depend drug ) , rule treat underlying systemic infection GvHD . 3 . Determine complement component activation , proinflammatory cytokine profile , baseline complement mutation . This include ELISA-based measure plasma C5a , C5b-9 , MASP-1-3 , tumor necrosis factor ( TNF ) -α , interferon-γ , pre-transplant complement mutational analysis . 4 . Assay participant plasma ability induce injury primary human microvascular endothelial cell ( MVEC ) , ability anti-C5 monoclonal antibody ( mAb ) ( Alexion , eculizumab ( Soliris ) ) anti-MASP2 ( Omeros , OMS721 ) mAb , block change investigator ' establish model . 5 . Define degree C5b-9 deposition sinusoidal CD34+ endothelial cell immunohistochemistry , ( IHC ) examine marrow core biopsy collect patient visit time TMA development . 6 . Correlate change plasma biomarkers , marrow sinusoidal C5b-9 deposition , vitro plasma-MVEC injury model treatment intervention treatment outcomes , choose transplant attend record observational cohort .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Thrombotic Microangiopathies</mesh_term>
	<criteria>participant schedule undergo allogeneic stem cell transplant willing consent genetic testing pregnant woman nurse mother woman childbearing potential unwilling use medically accept method contraception patient know contraindication use eculizumab patient tolerate plasma exchange</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>